High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes

Background Inflammatory breast cancer (IBC) is an aggressive form of BC poorly defined at the molecular level. We compared the molecular portraits of 63 IBC and 134 non-IBC (nIBC) clinical samples. Methodology/Findings Genomic imbalances of 49 IBCs and 124 nIBCs were determined using high-resolution array-comparative genomic hybridization, and mRNA expression profiles of 197 samples using whole-genome microarrays. Genomic profiles of IBCs were as heterogeneous as those of nIBCs, and globally relatively close. However, IBCs showed more frequent “complex” patterns and a higher percentage of genes with CNAs per sample. The number of altered regions was similar in both types, although some regions were altered more frequently and/or with higher amplitude in IBCs. Many genes were similarly altered in both types; however, more genes displayed recurrent amplifications in IBCs. The percentage of genes whose mRNA expression correlated with CNAs was similar in both types for the gained genes, but ∼7-fold lower in IBCs for the lost genes. Integrated analysis identified 24 potential candidate IBC-specific genes. Their combined expression accurately distinguished IBCs and nIBCS in an independent validation set, and retained an independent prognostic value in a series of 1,781 nIBCs, reinforcing the hypothesis for a link with IBC aggressiveness. Consistent with the hyperproliferative and invasive phenotype of IBC these genes are notably involved in protein translation, cell cycle, RNA processing and transcription, metabolism, and cell migration. Conclusions Our results suggest a higher genomic instability of IBC. We established the first repertory of DNA copy number alterations in this tumor, and provided a list of genes that may contribute to its aggressiveness and represent novel therapeutic targets.

[1]  T. Issad,et al.  Protein tyrosine phosphatase-1B and T-cell protein tyrosine phosphatase regulate IGF-2-induced MCF-7 cell migration. , 2010, Biochemical and biophysical research communications.

[2]  Andrea Bild,et al.  Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy , 2006, Clinical Cancer Research.

[3]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[4]  L. Machesky,et al.  Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B , 2005, Journal of Cell Science.

[5]  S. Merajver,et al.  Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells , 2005, Breast Cancer Research.

[6]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[7]  Hideyasu Matsuyama,et al.  Gain of 5p15.33 Is Associated with Progression of Bladder Cancer , 2007, Oncology.

[8]  S. Merajver,et al.  Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. , 2008, The American journal of pathology.

[9]  K. Helin,et al.  ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. , 2009, Cancer research.

[10]  M. Tremblay,et al.  Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-κB activation , 2001, Oncogene.

[11]  Hisataka Sabe,et al.  Interaction of Paxillin with Poly(A)-Binding Protein 1 and Its Role in Focal Adhesion Turnover and Cell Migration , 2005, Molecular and Cellular Biology.

[12]  C. Williams.  Inflammatory breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H Buerger,et al.  Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease , 2008, British Journal of Cancer.

[14]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Merajver,et al.  RhoC Induces Differential Expression of Genes Involved in Invasion and Metastasis in MCF10A Breast Cells , 2004, Breast Cancer Research and Treatment.

[16]  Wonshik Han,et al.  Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer , 2008, International journal of cancer.

[17]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Philippe Dessen,et al.  Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.

[21]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[22]  M. Boyd,et al.  Regulation of p53 and MDM2 Activity by MTBP , 2005, Molecular and Cellular Biology.

[23]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[24]  R. Wickner.  Host function of MAK16: G1 arrest by a mak16 mutant of Saccharomyces cerevisiae. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Merajver,et al.  WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer , 2003, Breast Cancer Research.

[26]  P. Vermeulen,et al.  Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer , 2010, Cancer.

[27]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[28]  Barbara J. Trask,et al.  Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.

[29]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[30]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[31]  M. A. Borrello,et al.  C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer , 2006, Molecular Cancer Therapeutics.

[32]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Merajver,et al.  WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. , 2004, Neoplasia.

[34]  A. Revenko,et al.  ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERα, is required for coregulator occupancy and chromatin modification , 2007, Proceedings of the National Academy of Sciences.

[35]  J. Reis-Filho,et al.  The role of molecular analysis in breast cancer , 2009, Pathology.

[36]  M. Denissenko,et al.  Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells , 2005, Molecular Cancer Therapeutics.

[37]  J. Kaufmann,et al.  Human Transcription Factor hTAFII150 (CIF150) Is Involved in Transcriptional Regulation of Cell Cycle Progression , 1999, Molecular and Cellular Biology.

[38]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  W. Jiang,et al.  Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. , 2009, European journal of cancer.

[40]  E. van Marck,et al.  Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.

[41]  Rosette Lidereau,et al.  BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer , 2008 .

[42]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[43]  Luc Y. Dirix,et al.  Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis , 2005, Breast Cancer Research and Treatment.

[44]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[45]  I. Van der Auwera,et al.  Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype , 2010, British Journal of Cancer.

[46]  P. Nederlof,et al.  Array-CGH and breast cancer , 2006, Breast Cancer Research.

[47]  E. van Marck,et al.  Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  J. Vishwanatha,et al.  Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells , 2009, Oncogene.

[49]  Kairong Cui,et al.  PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. , 2005, Genes & development.

[50]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[51]  S. Hilsenbeck,et al.  Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.

[52]  E. van Marck,et al.  Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer , 2008, Clinical Cancer Research.

[53]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[54]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[55]  John N Weinstein,et al.  A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.

[56]  S. Formenti,et al.  Translational control in cancer , 2010, Nature Reviews Cancer.

[57]  J. Lohi,et al.  Epsin 3 Is a Novel Extracellular Matrix-induced Transcript Specific to Wounded Epithelia* , 2001, The Journal of Biological Chemistry.

[58]  M. Espié,et al.  Two prognostic groups of inflammatory breast cancer have distinct genotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  S. Merajver,et al.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. , 2000, Neoplasia.

[60]  N. Ueno,et al.  The medical treatment of inflammatory breast cancer. , 2008, Seminars in oncology.

[61]  L. Zelek,et al.  Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers , 2000, Oncogene.

[62]  S. Merajver,et al.  WISP3 is a novel tumor suppressor gene of inflammatory breast cancer , 2002, Oncogene.

[63]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[64]  Tyler A. Ofstad,et al.  MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. , 2004, Genes & development.

[65]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[66]  S. Merajver,et al.  Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.

[67]  Y. Qi,et al.  Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer , 2011, Breast Cancer Research and Treatment.

[68]  R. Schneider,et al.  Inflammatory breast cancer cells are constitutively adapted to hypoxia , 2009, Cell cycle.

[69]  S. Merajver,et al.  Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer , 2004, Clinical & Experimental Metastasis.

[70]  Daniel Birnbaum,et al.  Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.

[71]  S. Barsky,et al.  Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma , 2002, Oncogene.

[72]  E. Resetkova.  Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. , 2008, Seminars in oncology.

[73]  S. Baserga,et al.  The small subunit processome is required for cell cycle progression at G1. , 2004, Molecular biology of the cell.

[74]  S. Merajver,et al.  Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. , 2002, Molecular cancer therapeutics.

[75]  M. Espié,et al.  Evidence of chromosome regions and gene involvement in inflammatory breast cancer , 2002, International journal of cancer.

[76]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[77]  S. Singletary,et al.  Defining the clinical diagnosis of inflammatory breast cancer. , 2008, Seminars in oncology.

[78]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[79]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[80]  S. Merajver,et al.  Molecular determinants of the inflammatory breast cancer phenotype. , 2008, Oncology.

[81]  P. Levine,et al.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.

[82]  S. Merajver,et al.  Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer , 2004, Breast Cancer Research and Treatment.

[83]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[84]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[85]  I. Brockhausen,et al.  The Relative Activities of the C2GnT1 and ST3Gal-I Glycosyltransferases Determine O-Glycan Structure and Expression of a Tumor-associated Epitope on MUC1* , 2001, The Journal of Biological Chemistry.

[86]  F. Bertucci,et al.  Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.